Daiwa Securities Group Inc. Cyma Bay Therapeutics, Inc. Transaction History

Daiwa Securities Group Inc.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Jan 31, 2024	BUY	$12.63 - $24.47 $1,553 - $3,009	123 Added 36.07%	464 $11,000
Q4 2022 Feb 06, 2023	BUY	$3.22 - $6.27 $608 - $1,185	189 Added 124.34%	341 $2,000
Q4 2020 Feb 04, 2021	SELL	$5.73 - $9.03 $1,294 - $2,040	-226 Reduced 59.79%	152 $1,000
Q1 2019 Apr 26, 2019	SELL	$8.16 - $13.42 $2,627 - $4,321	-322 Reduced 46.0%	378 $5,000
Q4 2018 Feb 05, 2019	BUY	$6.54 - $11.74 $4,578 - $8,218	700 New	700 $6,000

1.82M

Ticker CBAY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,677,904
Description
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of pri...

Get notified when there are updates to the investment portfolio of Daiwa Securities Group Inc., based on Form 13F filings with the SEC.

Stay updated on Daiwa Securities Group Inc. with notifications on news.